Momenta Pharmaceuticals Announces Proposed Public Offering of Common Stock
December 10 2019 - 4:04PM
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced that
it is commencing an underwritten registered public offering of
$200,000,000 of shares of its common stock. Momenta also expects to
grant the underwriters of the offering an option to purchase up to
an additional $30,000,000 of shares of its common stock,
exercisable for 30 days. All of the shares in the proposed offering
are to be sold by Momenta.
Goldman Sachs & Co. LLC and J.P. Morgan are acting as joint
lead book-running managers for the offering. Stifel is acting as a
book-running manager for the offering.
The offering is being made pursuant to an effective shelf
registration statement on Form S-3 that was filed with the U.S.
Securities and Exchange Commission (SEC) on August 8, 2019. A
preliminary prospectus supplement describing the terms of the
offering will be filed with the SEC and will form a part of the
effective registration statement. Copies of the preliminary
prospectus supplement and accompanying prospectus relating to the
offering may be obtained, when available, by contacting Goldman
Sachs & Co. LLC, Attention: Prospectus Department, 200 West
Street, New York, NY 10282, or by telephone: (866) 471-2526,
facsimile: (212) 902-9316 or by emailing
prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, or by telephone: (866) 803-9204; or Stifel, Nicolaus
& Company, Incorporated, Attention: Syndicate, One Montgomery
Street, Suite 3700, San Francisco, CA 94104, or by telephone: (415)
364-2720 or by emailing syndprospectus@stifel.com.
This press release shall not constitute an offer to sell, or the
solicitation of an offer to buy, nor shall there be any sale of
shares of these securities in any state or jurisdiction in which
such offer, solicitation, or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Momenta
Momenta Pharmaceuticals is a biotechnology company with a
validated innovative scientific platform focused on discovering and
developing novel therapeutics to treat rare, immune-mediated
diseases and advancing its late stage biosimilar portfolio. The
company is headquartered in Cambridge, MA.
Forward Looking Statements
Statements in this press release regarding future expectations,
beliefs, intentions, goals, strategies, plans or prospects, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including, but not
limited to, statements about the grant of an option to the
underwriters to purchase additional shares of common stock, the
filing and availability of a preliminary prospectus supplement, and
the Company’s expectations on the timing, size and completion of
the offering. Forward-looking statements may be identified by words
such as “believe,” “continue,” “plan to,” “potential,” “will,” and
other similar words or expressions, or the negative of these words
or similar words or expressions. Such forward-looking statements
involve known and unknown risks, uncertainties and other important
factors, including those referred to under the section “Risk
Factors” in the Company’s Quarterly Report on Form 10-Q for the
quarter ended September 30, 2019 filed with the Securities and
Exchange Commission, as well as other documents that may be filed
by the Company from time to time with the Securities and Exchange
Commission. As a result of such risks, uncertainties and factors,
the Company’s actual results may differ materially from any future
results, performance or achievements discussed in or implied by the
forward-looking statements contained herein. The Company is
providing the information in this press release as of this date and
assumes no obligations to update the information included in this
press release or revise any forward-looking statements, whether as
a result of new information, future events or otherwise.
INVESTOR CONTACT:Patty
EisenhaurMomenta
Pharmaceuticals1-617-395-5189IR@momentapharma.com |
MEDIA CONTACT:Karen
SharmaMacDougall 1-781-235-3060Momenta@macbiocom.com |
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Apr 2023 to Apr 2024